# Nectin Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nectin-therapeutics

- Industry: Biotechnology
- Headquarters: Jerusalem, Israel
- Website: www.nectintx.com
- Total disclosed funding: $5.4M
- Latest round: Series A (Nov 30, 2022)
- Investors on record: 7

## About

Established in 2017 and based in Jerusalem, Israel, Nectin Therapeutics Ltd. is a biotechnology company. In May 2024, Nectin Therapeutics Ltd. raised USD 10 million in venture funding from the Guangzhou-Israel Biotechnology Fund. As of 2024, the company is led by its CEO, Fabian Tenenbaum.

Nectin Therapeutics develops and offers next-generation immuno-oncology (IO) therapies for cancer patients. The firm’s portfolio of novel immuno-oncology products includes NTX1088, which is a first-in-class mAb used for the treatment of various solid tumors, and NTX2R13, which is a monoclonal antibody designed to target CD112R.

The company plans to use the funds raised in May 2024 to support its clinical research and boost its service offerings.

## Funding rounds

- Series A, Nov 30, 2022 — Peregrine Ventures, The University of Texas MD Anderson Cancer Center, Ochsner Clinic Foundation Retirement Plan, Israel Biotech Fund, aMoon, LSU Health Shreveport
- Series A, Mar 7, 2022, $5.4M — Cancer Focus Fund

## Investors

- Cancer Focus Fund (https://capitalatlas.ai/funds/cancer-focus-fund) — Series A
- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Series A
- The University of Texas MD Anderson Cancer Center — Series A
- Ochsner Clinic Foundation Retirement Plan — Series A
- Israel Biotech Fund (https://capitalatlas.ai/funds/israel-biotech-fund) — Series A
- aMoon (https://capitalatlas.ai/funds/amoon) — Series A
- LSU Health Shreveport — Series A